Snowball logo
logo
AZNC_logo

AstraZeneca PLC

$204.27$0.00  (0%)
Estimate
P/E
33.9
EPS
6.03
Beta
0.192
Forecast
P/E (FWD)
40.4
EPS (FWD)
5.06
Dividends
Dividend yield
2.09%
Annual payout
$4.27
Next ex. div date
February 20, 27
Payout
49.09%
Div.growth, 5y
13.31%
Dividend growth streak
1 year
Div.rating
About the company
Ticker
AZNCF
ISIN
GB0009895292
Country
United Kingdom
Sector (GICS)
Healthcare
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia. It has a strategic agreement with Tempus to develop the largest multimodal foundation model in oncology. The company has a collaboration agreement with IonQ, Inc. for the development of quantum-accelerated computational chemistry workflow for healthcare, life sciences, and chemistry; a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications and multiple next-generation therapies for obesity and type 2 diabetes; and collaboration Revna Biosciences for lung cancer treatment. AstraZeneca PLC was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the Uni

Frequently asked questions

What sector does AstraZeneca PLC (AZNCF) operate in?

AstraZeneca PLC belongs to the Healthcare sector and operates in the Drug Manufacturers - General industry.

What is AstraZeneca PLC (AZNCF) current stock price?

As of the latest data, AstraZeneca PLC stock price is $204.27, with a previous close of $204.27.

What is AstraZeneca PLC (AZNCF) current market capitalization?

AstraZeneca PLC market cap is approximately 316.68 billion.

What is AstraZeneca PLC (AZNCF) Earnings Per Share (EPS)?

The trailing EPS is $6.03, and the forward EPS is $5.06.

What is AstraZeneca PLC (AZNCF) Price-to-Earnings (P/E) ratio?

AstraZeneca PLC current P/E ratio is 33.88, with a forward P/E of 40.37.

Does AstraZeneca PLC (AZNCF) pay dividends?

Yes. AstraZeneca PLC pays semiannual dividends with an annualized yield of 2.09% and an estimated annual payout of $4.27 per share.

When is the next ex-dividend date for AstraZeneca PLC (AZNCF)?

The next ex-dividend date is scheduled for February 20, 2027.

What is AstraZeneca PLC (AZNCF) beta (volatility) score?

AstraZeneca PLC has a beta of 0.192, indicating lower volatility than the overall market.